title: Inhibitory effect of hypoxia inducible factor-1 antisense oligonucleotide on growth of human hepatocellular carcinoma cells.
abstract: OBJECTIVE
  To observe the inhibitory effect of Hypoxia inducible factor-1 antisense oligonuclecotide on growth of human hepatocellular carcinoma cells and gene expression of HIF-1, in order to seek a new gene therapy for hepatocellular carcinoma.
  
  
  METHODS
  Six Hypoxia inducible factor-1 antisense oligonuclecotides with various concentrations (0.2 micromol/l, 0.4 micromol/l, and 0.8 micromol/l) were transformed into HepG2 cells by lipofectamine reagent. 72 h after transfection, MTS assay was used to detect cellular proliferation. In addition, Hypoxia inducible factor-1 antisense oligonuclecotide2 with various concentrations (0.2, 0.4, 0.8, and 1.0 micromol/l) were transformed into HepG2 cells. About 48 h after transfection, reverse transcription-polymerase chain reaction assay and Western Blot assay were employed to detect the expression of Hypoxia inducible factor-1 gene and the synthesis of Hypoxia inducible factor-1 protein respectively.
  
  
  RESULTS
  HepG2 cell growth was inhibited by 6 Hypoxia inducible factor-1 antisense oligonuclecotides at various concentrations. Among them, Hypoxia inducible factor-1 antisense oligonuclecotide2 showed the most effective inhibition ability (P < 0.01), the inhibitory rate was 89.66% at the concentration of 1.0 micromol/l. About 48 h after transfection, Hypoxia inducible factor-1 mRNA expression was downregulated and Hypoxia inducible factor-1 protein synthesis was decreased by antisense oligonuclecotide2.
  
  
  CONCLUSIONS
  The hepatocellular carcinoma cell proliferation was inhibited by Hypoxia inducible factor-1 antisense oligonuclecotide. Moreover, the gene expression and protein synthesis of Hypoxia inducible factor-1 were reduced by Hypoxia inducible factor-1 antisense oligonuclecotide. The findings suggested that antisense technique targeting Hypoxia inducible factor-1 might be an effective gene therapy of human hepatocellular carcinoma.
authors.affiliation: Department of Gastroenterology, First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, 310003, China.
authors.forename: Chen
authors.initials: C
authors.lastname: WeiXing
authors.forename: Hu
authors.initials: H
authors.lastname: Tiantian
authors.forename: Ni
authors.initials: N
authors.lastname: Qun
authors.forename: Yu
authors.initials: Y
authors.lastname: Chaohui
authors.forename: Xu
authors.initials: X
authors.lastname: Ping
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000628:therapy; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000235:genetics; D008113:Liver Neoplasms / Q000473:pathology* / Q000628:therapy; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis
chemical_list: D051793:Hypoxia-Inducible Factor 1; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger